Adnexal Tumors and Masses: Symptoms, Causes, Treatment & Nursing Care

Clinicians use “adnexal mass” language to describe enlargement arising from ovarian parenchyma, the fallopian tube, or mullerian-adjacent tissues that sonographically appear contiguous with the ovary. Lesions range from transient follicular or corpus luteum physiology through endocrine-active stromal tumours, endometriotic implants forming cystic collections (overview of endometriosis), mature teratomas, epithelial neoplasms, tubal pathology, and metastatic deposits that secondarily involve the adnexa.

Because the differential spans self-limited conditions and time-sensitive surgical disease, clinicians anchor decisions on symptom tempo, hormonal milieu, pregnancy status, and vascularity/morphology on expert ultrasound rather than on any single clinic variable. Multidisciplinary pathways increasingly encode ultrasound-based probability tools (IOTA descriptors, risk scores, O-RADS-style categories) so referring teams can align language with gynecology and oncology services—nursing documentation that copies exact radiology phrases (“solid papillary component,” “low-level internal echoes,” “increased central vascularity”) materially speeds downstream reviews.

Formal scoring systems vary by institution, but bedside reasoning still clusters findings into classic benign patterns, indeterminate / intermediate lesions, and high-suspicion morphology. The table below is a teaching scaffold—always defer to your radiology report category and local gynecology consensus.

Many masses are silent and discovered during imaging for unrelated complaints. Symptomatic presentations cluster around visceral distension, traction on supportive ligaments, hormone secretion, infection, or complication of a cyst.

Typical symptom patterns

• Dull pressure, heaviness, or exercise-limiting pelvic pain that may fluctuate with the cycle.
• Early satiety or progressive abdominal bloating when mass effect competes with gastric room.
• Urinary frequency or constipation from anatomical displacement—often misread as simple UTI until examination clarifies.

Atypical or easy-to-dismiss cues

• Subacute lower abdominal pain ascribed to irritable bowel in a postmenopausal patient with new palpable fullness.
• Unexplained iron deficiency when heavy bleeding coexists with submucosal fibroids masquerading as “adnexal overlap” on limited imaging—link uterine fibroids pathways when anatomy clarifies.
• Virilisation, early precocious puberty, or postmenopausal bleeding driven by rare hormone-active tumours (escalate rather than monitor silently).

Physiologic / functional cysts dominate premenopausal imaging, reflecting incomplete ovulation dynamics or pregnancy-related corpora. Neoplastic causes span benign cystadenomas, mature teratomas, borderline tumours, epithelial ovarian cancers, sex cord–stromal neoplasms, germ cell tumours in younger patients, and fallopian tube primaries that present as adnexal thickening. Inflammatory collections after STI-related PID or post-procedural infection create complex adjacent masses already discussed under acute infection pathways above.

Risk accelerators for malignancy include advancing age, hereditary BRCA1/2 or Lynch syndrome context (see national familial cancer pathways), endometriosis cohorts with changing sonographic character, nulliparity, and long-standing polycystic ovary syndrome only indirectly via ovulation patterns—not as a direct transformation narrative.

Clinical assessment

Quantify pain scores with timestamps, cycle day (if premenopausal), fever curve, vaginal bleeding pattern, bowel or urinary dysfunction, and prior fertility therapy. Bimanual examination may clarify uterine versus adnexal origin yet can be limited by habitus—do not equate “normal exam” with ruling out torsion or abscess when symptoms clash.

Laboratory investigations

• Pregnancy testing wherever ectopic remains plausible regardless of stated contraception.
• CA-125 / HE4 and related markers—interpret only in pathway-defined combinations; remember overlap with endometriosis and benign fibroids.
• Complete infection panel when septic—including blood cultures per protocol, PCR platforms for cervical infection where guideline-directed.
• Hemoglobin if bleeding, suspected hemoperitoneum, or preoperative baseline.

Imaging

Expert pelvic ultrasound with Doppler remains the modality that distinguishes benign thin-walled cysts from lesions meriting oncology choreography. When ultrasound cannot confidently score risk—especially for surgical planning of deeply infiltrating endometriosis or large heterogeneous tumours—magnetic resonance imaging supplements rather than replaces first-line TVS.

Risk scores and structured reporting

Radiologists often communicate IOTA “simple-rules versus non-simple” conclusions or O-RADS categories so referral letters stay congruent. If your hospital uses proprietary calculators, mirror their thresholds when discussing case urgency with gynecology registrars.

1. Stabilise and risk-sort: Airway, circulation, pregnancy status, focused sepsis screen—before outpatient booking conversations.
2. Image with expertise: Arrange TVS; obtain prior comparator studies if external transfers arrive with incomplete discs.
3. Probability label: Align radiology category (benign vs intermediate vs high) with history—resolve conflicts through gynecology MDT slots, not guesswork.
4. Biomarkers with discipline: Order CA-125/HE4 per pathway, not reflexively “to reassure.”
5. Select therapy lane: Observation with scheduled repeat scan, antibiotic bundle + monitoring, operative cystectomy/oophorectomy, or cancer staging surgery as indicated.
6. Safety-net before discharge: Red-flag education, NSAID analgesia when appropriate per local formulary (for example ibuprofen), and ondansetron or pathway-equivalent antiemetics when vomiting threatens hydration.

First-line management themes

• Expectant surveillance for validated low-risk premenopausal simple cysts with reliable follow-up—document who orders the repeat scan.
• Operative management for persistent symptomatic masses, high-risk morphology, torsion, rupture with hemodynamic impact, or abscess refractory to antibiotics.
• Oncology-integrated surgery when frozen section or preoperative scoring places the patient on an epithelial ovarian cancer staging trajectory—coordinate theatres, blood products, and stoma counselling as pathways dictate.

Second-line or contextual alternatives

• Hormonal suppression may feature in recurrent benign functional cyst nuisance—but only after benignity criteria are secure, never as a substitute for red-flag exclusion.
• Where polycystic ovary syndrome complicates metabolic risk, coordinate weight and glycaemic care; metformin may appear in parallel metabolic plans without treating the mass itself.

Special populations

• Pregnancy: Balance fetal considerations with surgical urgency for torsion or uncertain malignant potential—obstetrics plus gynecology consensus.
• Adolescents: Favour ovarian-preserving techniques when safe; ACOG Committee Opinion 783 guides nuanced torsion decisions.
• Older adults / frailty: Apply opioid protocols cautiously—morphine only with monitoring and prescriber alignment; emphasise early mobilisation after minimal-access surgery.

• Monitoring intervals: After low-risk premenopausal surveillance plans, book repeat imaging before the patient leaves clinic—6–12 weeks is a frequent teaching anchor but must match radiology wording.
• Treatment failure signals: Pain exceeding expected trajectory, enlarging mass on interval scan, new ascites, or unexplained weight loss triggers upgrade, not passive reassurance.
• Drug–drug checks: Antiemetics, antibiotics, perioperative anticoagulation, and QT-prolonging stacks require pharmacist review especially with renal impairment.
• Referral thresholds: Any reporting system classifying high suspicion, postmenopausal new solid components, or acute pain with concerning Doppler findings should bypass routine queues.

• Ovarian infarction after neglected torsion.
• Hemodynamic collapse from hemoperitoneum or septic shock.
• Fertility compromise if delayed salvage of torsed ovary or overly aggressive resection without counselling.
• Venous thromboembolism, ileus, or vault bleeding after major staging surgery—tie observations to enhanced recovery bundles.

No public-health intervention removes sporadic adnexal masses. Clinician-facing risk reduction focuses on timely symptom pathways (for example NICE NG12-style referral discipline), cascade genetic testing where familial ovarian cancer risk guidance applies, and STI control to limit downstream PID/abscess disease.

Benign lesions often regress or remain stable with surveillance; borderline tumours require prolonged clinical follow-up; invasive epithelial cancers depend on stage and cytoreductive completeness—defer numeric survival commentary to oncology teams once histology returns. Nursing interactions should avoid premature certainty while still providing structured next-step clarity (appointments, expected symptoms, alarm symptoms).

• Carry forward verbatim ultrasound impressions in handovers—paraphrasing loses risk stratification fidelity.
• Screen tactfully for intimate partner violence when patients repeatedly miss follow-up yet return via emergency routes.
• Use professional interpreters for suspected-malignancy discussions.
• Watch for vagal symptoms during large-volume paracentesis or rapid ascites shifts on oncology admissions.

• Track early warning scores in febrile pelvic pain syndromes—single “normal” vitals mislead.
• Reassess analgesia and antiemetics 30–60 minutes after first interventions in acute presentations.
• Chart drain outputs and urine volume postoperatively; pair electrolytes with drain losses.
• VTE prevention: mechanical plus pharmacologic thromboprophylaxis until ambulatory targets met—unless contraindicated.
• Labs: Serial hemoglobin if hemorrhage suspected; infection markers aligned with sepsis bundles.

• Sudden severe pelvic pain with vomiting, syncope, or shoulder-tip pain.
• Fever with rigors plus pelvic peritonism and known/suspected complex mass.
• Hypotension, tachycardia, or acute anemia without overt external bleeding.
• Positive pregnancy test with pain and adnexal abnormality until ectopic protocols clear risk.

Rising pain scores despite opioids, new distension, or confusion in older adults should reset the differential toward perforation, sepsis, or hemorrhage.

Objective cues

• Worsening lactate, oliguria, or oxygen need in suspected TOA sepsis.
• Falling hemoglobin without external losses.
• New pleuritic pain or unilateral calf swelling postoperatively—evaluate for embolic disease per pathway.

Escalation mechanics

• Trigger critical care outreach when early warning scores breach institutional limits.
• Engage on-call gynecology immediately for suspected torsion even when ultrasound is pending transport.
• Route rapidly to tertiary oncology MDT coordinators when staging imaging suggests carcinomatosis.

Pre-treatment

• Confirm fasting instructions, anticoagulant holds, and glycaemic plans per anaesthesia.
• Modesty-centred preparation for repeated pelvic assessments.

Perioperative / inpatient

• Monitor ileus cues, shoulder-tip pain after laparoscopy, and surgical drain trends.
• QT monitoring per policy when multiple QT-prolonging antiemetics or antibiotics cluster.

Education & evaluation

• Teach-back on wound care, VTE prevention, and alarm symptoms prior to discharge.
• Measure effectiveness through attended follow-up imaging and documented symptom diaries—not sole telehealth reassurance.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of adnexal mass evaluation (IOTA / RMI / ROMA), pre- vs postmenopausal triage, ovarian-torsion red flags and gynaecologic-oncology referral criteria.